Effect of switch from metformin / vildagliptin fixed-dose combination tablet to metformin / anagliptin fixed-dose combination tablet - Effect of switch from metformin / vildagliptin fixed-dose combination tablet to metformin / anagliptin fixed-dose combination tablet

Kurihara Clinic of Internal Medicine0 个研究点目标入组 142 人开始时间: 2020年6月30日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Patients who are treated by combination of metformin / vildagliptin fixed-dose combination tablet LD and HD 2. Patients who changed the dose of metformin / vildagliptin fixed-dose combination tablet during the metformin / vildagliptin fixed-dose combination tablet administration period 3. Patients who changed the dose of metformin / anagliptin fixed-dose combination tablet during the metformin / anagliptin fixed-dose combination tablet administration period 4. Patients who changed the type or dose of hypoglycemic agents or antihyperlipidemic agents 5. Patients who are treated by dialysis or patients with severe renal impairment (eGFR < 30 mL/min/1.73m2) at baseline 6. Female patients who are pregnant, breastfeeding, possibly pregnant, or planning to become pregnant 7. Patients who denied the use of clinical medical records to the study 8. Patients with any conditions that physicians thought to be inappropriate to participate in the study such as poor adherence

发起方

Kurihara Clinic of Internal Medicine